Swiss Franc Surge Squeezes Export Margins as Safe-Haven Flows Deepen Currency Trap

The Swiss franc hit an 11-year high against the dollar in January, cementing its status as the premier safe-haven currency—but the same capital inflows driving that strength are now compressing margins at export-dependent manufacturers from watchmakers to precision engineers. The franc gained 13% against the dollar in 2025 and another 3% in early 2026, reaching levels not seen since the 2015 shock de-pegging from the euro, per CNBC. Bloomberg reported Morgan Stanley forecasting a potential further 17% appreciation to 0.64 per dollar in a bear-case scenario, calling the franc “arguably the most ‘gold-like’ safe haven currency.”

Margin Squeeze Hits Machinery and Watches Hardest

The currency rally is translating into measurable economic pain. SWI swissinfo.ch quoted Nicola Tettamanti, president of industry group Swissmechanic, warning that the franc’s strength “is increasingly undermining the competitiveness of Switzerland’s machinery, electrical engineering and metals industry.” UBS analysis cited by the outlet estimates that every 1% franc appreciation erodes listed Swiss company profits by an average of 0.9%.

Swiss Manufacturing PMI fell to 47.4 in February from 48.8 in January, marking a three-year stretch below the 50-point expansion threshold, according to Trading Economics. The February reading showed production dropping to 45.8 and the order book index sliding 7.1 points to 41.1. Employment also declined, falling 3.5 points to 46.4. According to research from CEPR, a 10% franc appreciation reduces Swiss capital goods exports by 6%, with specialized machinery and precision instruments particularly vulnerable.

Pharma giant Roche told investors it expects a four-percentage-point currency headwind to 2026 results, according to SWI swissinfo.ch. The pharmaceutical and chemical sector, which accounts for 53% of Swiss exports at CHF 152 billion annually, saw exports to the U.S. complicated further by the residual 15% tariff negotiated down from 39% in late 2025.

SNB Policy Divergence Amplifies Haven Premium

The franc’s strength reflects not just geopolitical uncertainty but also widening Monetary Policy divergence. Switzerland’s inflation rate registered 0.1% in February 2026, while the SNB holds its policy rate at zero—starkly different from the European Central Bank’s 2.15% deposit rate and the Federal Reserve’s 4.5% target range. The SNB lowered its 2026 inflation forecast to 0.3% in December, signaling tolerance for prolonged disinflation, per Morningstar.

That policy gap creates a structural bid for the franc. While the Fed debates the pace of easing and the ECB has largely completed its cutting cycle, the SNB operates in near-deflationary conditions with no immediate room to tighten. ECB monetary policy blog analysis shows that U.S. rate hikes initially weaken the euro (and by extension pressure the franc higher via safe-haven flows), then transmit disinflationary pressure through tighter financial conditions—a dynamic that reinforces Switzerland’s low-inflation trap.

SNB Chairman Martin Schlegel told CNBC in January that geopolitical escalation “means more uncertainty,” adding that “the Swiss franc is a safe haven. Whenever there is uncertainty in the world, the Swiss franc appreciates, and this makes monetary policy more complicated.” The central bank’s room to maneuver is constrained by political sensitivity around FX intervention—the U.S. Treasury added Switzerland to its currency manipulation watch list in Q2 2025, citing CHF 1 billion in 2024 interventions.

Sector-Level Divergence: Pharma Resilient, Machinery Exposed

Currency sensitivity varies sharply by product sophistication. Research published by CEPR found no evidence that franc appreciation reduces exports of watches or pharmaceuticals—demand for these high-technology, price-inelastic goods remains stable. But capital goods, precision instruments and machinery face a different reality: a 10% appreciation causes Swiss franc export prices for capital goods to fall 4%, compressing margins as producers absorb currency losses to maintain market share.

According to CNBC, Giuliano Bianchi of EHL Hospitality Business School noted: “The Swiss franc remains strong in part because demand for many Swiss exports is relatively price-inelastic.” In pharmaceuticals and precision manufacturing, currency appreciation “does little to reduce foreign demand, weakening the mechanism that would otherwise stabilize the exchange rate.”

That bifurcation creates policy headaches. Pharma exports hit a record CHF 152 billion in 2025, up CHF 3.3 billion, driven by serums and vaccines, according to Switzerland’s Federal Office for Customs and Border Security. But machinery and electronics posted their third consecutive annual decline. The February manufacturing PMI details show purchasing volumes at 42.2 and stocks of purchased goods at 42.5—both deep in contraction.

What to Watch

The EUR/CHF exchange rate is the critical threshold. Analysts at SWI swissinfo.ch flagged 0.90 as a level that would “trigger some difficult conversations” for policymakers and put exporters under severe pressure. The pair traded at 0.918 in late February; Credit Agricole noted the SNB is “surely watching those developments closely” despite no uptick in anti-franc jawboning.

Intervention remains the SNB’s preferred tool over negative rates, which Chairman Schlegel called a high bar. But the Trump administration’s prior designation of Switzerland as a currency manipulator in 2020 constrains overt FX operations. The SNB intervened only once significantly in 2025—on April 2, “Liberation Day,” following U.S. global tariff announcements, per Morningstar.

Investors should monitor monthly inflation prints for any uptick that would relieve disinflationary pressure, and track the 10-year Bund-Swiss yield differential—currently at 2.6 percentage points, creating a structural tailwind for EUR/CHF weakness. Any breach below 0.90 on sustained volume would likely force the SNB’s hand, risking renewed U.S. trade tensions. For exporters outside pharma and luxury goods, the margin compression has moved from cyclical headwind to structural challenge—one that productivity gains can offset only temporarily.